Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.70 |
| ▸ | DRD1 | P21728 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.70 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30669880 | 1.00 | TBXA2R (0.70) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| Benzene SCHEMBL7444141 | 1.00 | TBXA2R (0.70) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL34462108 | 1.00 | TBXA2R (0.70) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL16634960 | 1.00 | TBXA2R (0.70) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| Maleic Acid SCHEMBL6822788 | 0.95 | TBXA2R (0.64) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL2846047 | 0.93 | CYP3A4 (0.75) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL6299952 | 0.93 | CYP3A4 (0.75) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| Benzene SCHEMBL3268864 | 0.93 | ABCB11 (0.82) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL30471867 | 0.93 | ABCB11 (0.82) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL3183503 | 0.93 | ABCB11 (0.82) | TBXA2RADRA1ASLC6A3HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111097050-A | Composition comprising fatty acid or derivative thereof and phenylpyridine derivative | 黄泳华 | 2020-05-05 | — | — | CN | claimed |
| EP-1435954-B1 | A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE | LEK PHARMACEUTICALS (SI) | 2010-01-13 | — | — | EP | claimed |
| WO-2007131759-A1 | A PROCESS FOR THE PREPARATION OF AMLODIPINE BENZENESULFONATE | LEK PHARMACEUTICALS D.D. (SI) | 2007-11-22 | — | — | WO | claimed |
| EP-0599220-B1 | A process for the preparation of amlodipine benzenesulphonate | LEK TOVARNA FARMACEVTSKIH (SI) | 1996-08-14 | — | — | EP | claimed |
| US-12005141-B2 | Pharmaceutical solution of amlodipine | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-06-11 | — | — | US | disclosed |
| CN-112955965-B | Method for lowering blood pressure using dihydropyridine calcium channel blocker pharmaceutical compositions | 阿斯利康(英国)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230414591-A1 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES | TAVANTA THERAPEUTICS HUNGARY INCORPORATED (HU) | 2023-12-28 | — | — | US | disclosed |
| US-20230330018-A1 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-10-19 | — | — | US | disclosed |
| US-11766428-B2 | Topical amlodipine salts for the treatment of anorectal diseases | TAVANTA THERAPEUTICS HUNGARY INCORPORATED (HU) | 2023-09-26 | — | — | US | disclosed |
| US-11723866-B2 | Pharmaceutical solution of amlodipine | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230181598-A1 | FORMULATIONS AND METHODS OF TREATING COVID-19 AND PREVENTING INFECTION WITH SARS-CoV-2 | CARRAIG SLAINTE LIMITED (IE) | 2023-06-15 | — | — | US | disclosed |
| EP-1013275-A2 | Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine | SEPRACOR, INC. (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0599220-B1 | A process for the preparation of amlodipine benzenesulphonate | LEK TOVARNA FARMACEVTSKIH (SI) | 1996-08-14 | — | — | EP | disclosed |
| US-5438145-A | Process for the preparation of amlodipine benzenesulphonate | LEK, TOVARNA FARMECEVTSKIH IN KEMICNIH IZDELKOV (SI) | 1995-08-01 | — | — | US | disclosed |
| EP-0661970-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPERTENSION, ANGINA AND OTHER DISORDERS USING OPTICALLY PURE (-) AMLODIPINE | SEPRACOR, INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5389654-A | 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate | LEK, TOVARNA, FARMACEVTSKIH IN KEMICNIH . . . (SI) | 1995-02-14 | — | — | US | disclosed |
| EP-0661970-A4 | METHODS AND COMPOSITIONS FOR TREATING HYPERTENSION, ANGINA AND OTHER DISORDERS USING OPTICALLY PURE (-) AMLODIPINE. | SEPRACOR INC (US) | 1994-12-16 | — | — | EP | disclosed |
| EP-0599220-A1 | A process for the preparation of amlodipine benzenesulphonate | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993010779-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPERTENSION, ANGINA AND OTHER DISORDERS USING OPTICALLY PURE (-) AMLODIPINE | SEPRACOR, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414591-A1 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES | APC, ANO2, SLC10A2 | TBXA2R 1988/4885ADRA1A 707/4885SLC6A3 2895/4885 |
| US-11723866-B2 | Pharmaceutical solution of amlodipine | GK, CACNA1C, CACNA1I | TBXA2R 968/4885ADRA1A 215/4885SLC6A3 888/4885 |
| US-12005141-B2 | Pharmaceutical solution of amlodipine | GK, CACNA1C, CACNA1I | TBXA2R 968/4885ADRA1A 215/4885SLC6A3 888/4885 |
| US-20230330018-A1 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | GK, CACNA1C, CACNA1I | TBXA2R 968/4885ADRA1A 215/4885SLC6A3 888/4885 |
| US-11766428-B2 | Topical amlodipine salts for the treatment of anorectal diseases | APC, ANO2, SLC10A2 | TBXA2R 1988/4885ADRA1A 707/4885SLC6A3 2895/4885 |
| US-20230181598-A1 | FORMULATIONS AND METHODS OF TREATING COVID-19 AND PREVENTING INFECTION WITH SARS-CoV-2 | ACE2, ACE, NR3C2 | TBXA2R 490/4885ADRA1A 335/4885SLC6A3 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.